Boryung said Tuesday it has signed a license-in agreement with Antengene, a China-based oncology drug developer, for the blood cancer drug Xpovio (selinexor).
Under the deal, Boryung secured exclusive rights in South Korea, including sales, distribution and regulatory approval. The company began full-scale domestic supply in February.
Xpovio, developed by Antengene, is a treatment for multiple myeloma and diffuse large B-cell lymphoma. It is described as the world’s first-in-class selective inhibitor of XPO1, a nuclear export protein. By inhibiting nuclear export, tumor suppressor and growth-regulating proteins are retained in the cell nucleus, where they accumulate and activate, inducing cancer cell death.
Multiple myeloma often becomes resistant to existing drugs as treatment continues, creating demand for therapies with different mechanisms. Boryung said Xpovio is drawing attention as an additional option for patients with relapsed or refractory multiple myeloma who have limited choices. It is an oral formulation, not an injection, which can improve convenience for long-term treatment.
Xpovio is reimbursed for combination therapy with dexamethasone for fifth-line or later treatment. Starting March 1, reimbursement was also expanded to combination therapy with bortezomib and dexamethasone for second-line or later treatment.
Dong-A Pharm said Tuesday it has launched Panpyrin Time powder, a cold medicine designed to dissolve in the mouth without water.
The powder can be taken anytime and anywhere when cold symptoms appear, the company said. It contains acetaminophen, chlorpheniramine, riboflavin, tipepidine and DL-methylephedrine, which it said may help relieve runny nose, sore throat, fever, cough and muscle aches.
Dong-A Pharm said it does not add sugar, coloring, caffeine or preservatives, and includes vitamin B2 to help support recovery from cold symptoms.
The product applies the company’s patented OD!FS formulation technology, designed to dissolve quickly with a small amount of saliva. Dong-A Pharm said it uses a fine-particle structure and special surface treatment to minimize bitterness, and adds a lemon flavor. The stick-type powder is designed for portability and can be taken by people ages 2 and older, including seniors, the company said.
Daewoong Pharmaceutical said Tuesday that Phase 3 results for its next-generation tablet bowel preparation, CleanCol, were published in the SCI-indexed World Journal of Gastroenterology.
Daewoong said CleanCol reduces sulfate ingredients by 25% compared with existing products and cuts the number of tablets to 20 to ease the burden of dosing. It also adds picosulfate, an ingredient that helps promote bowel movements.
In the study, CleanCol maintained a similar level of bowel-cleansing efficacy compared with an existing bowel preparation, the company said. The overall rate of adverse drug reactions was significantly lower at 18.10% for CleanCol, compared with 33.02% for the existing bowel preparation.
The paper was based on a multicenter, randomized Phase 3 trial involving 215 adults at seven university hospitals in South Korea. Principal investigator Park Dong-il, a professor at Kangbuk Samsung Hospital, said, “It will help reduce the burden patients experience during colonoscopy preparation and improve medication adherence.”
GC Wellbeing said Tuesday it received a citation from the governor of Chungcheongbuk-do for helping prevent the spread of a fire and supporting firefighting efforts. The award was presented at a ceremony held Monday at the provincial government complex.
The company said the citation formally recognizes its disaster-response efforts during a fire at the Hybaro plant. Chungcheongbuk-do Gov. Kim Young-hwan presented the award to Park Dong-hwan, head of production at GC Wellbeing, according to the company.
GC Wellbeing said it did not suffer direct facility damage from the fire, but incurred losses from suspended operations, lost workdays, and disposal costs for raw and subsidiary materials. The province highly evaluated the company’s proactive response to help protect community safety and its close cooperation with the public response system, it said.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.